AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study

By Colin Kellaher

AbbVie on Thursday said a late-stage study of its recently acquired tavapadon drug candidate for the neurodegenerative disorder Parkinson's disease hit its key goals.

AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline versus placebo in adults with early Parkinson's.

The North Chicago, Ill., biopharmaceutical company said the study also met a key secondary endpoint, showing statistically significant improvement in motor aspects of experiences of daily living, adding that it expects results from a Phase 3 study of tavapadon as a flexible-dose monotherapy by the end of the year.

AbbVie said it plans to use full results from the study to support regulatory submissions of tavapadon as a treatment for Parkinson's disease. The company picked up tavapadon as part of its recently completed $8.7 billion acquisition of Cerevel Therapeutics.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 26, 2024 08:40 ET (12:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.